PPP1R15B

Chr 1AR

protein phosphatase 1 regulatory subunit 15B

Also known as: CREP, MSSGM2

This gene encodes a protein phosphatase I-interacting protein that promotes the dephosphorylation of eukaryotic translation initiation factor 2A to regulate translation under conditions of cellular stress. The transcribed messenger RNA contains two upstream open reading frames (ORFs) that repress translation of the main protein coding ORF under normal conditions, while the protein coding ORF is expressed at high levels in response to stress. Continual translation of the mRNA under conditions of eukaryotic translation initiation factor 2A inactivation is thought to create a feedback loop for reactivation of the gene during recovery from stress. In addition, it has been shown that this protein plays a role in membrane traffic that is independent of translation and that it is required for exocytosis from erythroleukemia cells. Allelic variants of this gene are associated with microcephaly, short stature, and impaired glucose metabolism. [provided by RefSeq, Feb 2016]

Primary Disease Associations & Inheritance

Microcephaly, short stature, and impaired glucose metabolism 2MIM #616817
AR
0
Active trials
12
Pathogenic / LP
243
ClinVar variants
6
Pubs (1 yr)
-1.3
Missense Z
0.51
LOEUF
Clinical SummaryPPP1R15B
Population Constraint (gnomAD)
Constrained for loss-of-function variants (OE-LoF 0.26) despite low pLI — interpret in context.
📋
ClinVar Variants
12 Pathogenic / Likely Pathogenic· 169 VUS of 243 total submissions

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Moderate LoF intolerance
LoF Constraint
0.51LOEUF
pLI 0.151
Z-score 3.33
OE 0.26 (0.140.51)
Moderately constrained

More LoF-intolerant than ~75% of genes

Missense Constraint
-1.35Z-score
OE missense 1.20 (1.111.30)
431 obs / 359.1 exp
Tolerant

Tolerant to missense variation

Observed / Expected Ratios
LoF OE0.26 (0.140.51)
00.351.4
Missense OE1.20 (1.111.30)
00.61.4
Synonymous OE1.08
01.21.6
LoF obs/exp: 6 / 23.4Missense obs/exp: 431 / 359.1Syn Z: -0.79
DN
DN
0.6261th %ile
GOF
0.6346th %ile
LOF
0.4038th %ile

The Badonyi & Marsh model scores gain-of-function highest, but genomic evidence most strongly supports dominant-negative as the primary mechanism.

DNprediction above median

Note: In-silico variant effect predictors (SIFT, PolyPhen, REVEL, CADD) may underestimate pathogenicity of missense variants in genes with GOF or DN mechanisms. Consider functional evidence and clinical context.

Predictions from Badonyi M, Marsh JA. PLoS ONE. 2024;19(8):e0307312.

ClinVar Variant Classifications

243 submitted variants in ClinVar

Classification Summary

Pathogenic11
Likely Pathogenic1
VUS169
Likely Benign50
Benign8
Conflicting4
11
Pathogenic
1
Likely Pathogenic
169
VUS
50
Likely Benign
8
Benign
4
Conflicting

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
0
0
11
0
11
Likely Pathogenic
0
0
1
0
1
VUS
2
157
10
0
169
Likely Benign
0
10
3
37
50
Benign
0
5
1
2
8
Conflicting
4
Total21722639243

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

PPP1R15B · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

Gene2Phenotype Curations

PPP1R15B-related severe microcephaly, short stature, and intellectual disability

limited
ARLoss Of FunctionAbsent Gene Product
Dev. Disorders
G2P ↗

Gene2Phenotype curations · DECIPHER consortium patient cohort (public variants) · deciphergenomics.org

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

No active trials found for this gene.

Search ClinicalTrials.gov →
Clinical Literature
Landmark / reviewRecent case evidence
Recent Gene-Specific Literature
Gene in title · MEDLINE · newest first
Europe PMC